17p Deletion in Chronic Lymphocytic Leukemia: Risk Stratification and Therapeutic Approach

摘要: Treatment of chronic lymphocytic leukemia has greatly advanced in the past few years since introduction fludarabine/cyclosphosphamide/rituximab regimen as first-line therapy. Nevertheless, 17p deletion represents a challenge because conventional treatment does not provide satisfactory results. and TP53 mutation are major factors accounting for rapid disease progression, poor response to therapy, early relapse, short survival. Allogeneic stem cell transplantation harbors curative potential but also considerable morbidity mortality. Novel agents acting independently p53 signaling pathway, with favorable side-effect profiles, promising. This review summarizes up-to-date knowledge about spectrum options.